Quality | 2021.08.18
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results ended June 30th, 2021, sharing the company\'s recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]iven-innovation-301358032.html
